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INTRODUCTION:  Neuroendocrine  tumors  of  the  small  intestine  represent  about  half  of all  small  intestine
neoplasms.  Recurrence  after  surgery  with  curative  intention  is frequently  observed  but recurrence  rate
has not  yet  been  described  or analyzed  sufﬁciently.
PRESENTATION  OF  CASE:  In this  case  bilocal  recurrence  4  years  after  curative  surgery  of  an ileocoecal
neuroendocrine  carcinoma  was  observed  in  a 64  year  old  female.  Diagnosis  and follow-up  was  carried  out
as  proposed  in current  ENETS  guidelines  using  somatostatin  receptor  scintigraphy  for  primary  diagnosis
and  Ga-DOTATOC-PET/CT  in  follow-up.
DISCUSSION:  We  can  conﬁrm  that  PET/CT  for somatostatin  receptor  imaging  shows  good  sensitivity  in
detecting  neuroendocrine  neoplasms  and  should  be preferred  for diagnostic,  if available.  For  individual
adaptation  of  follow-up  procedures,  as far as  time  intervals  and  preferred  imaging  methods  are  concerned,
research on  recurrence  rate  and  long  term  outcome  after  curative  surgery  should  be  extended.
CONCLUSION:  Livelong  follow-up  after  surgical  resection  of  neuroendocrine  tumors  is  necessary  and
Ga-DOTA/TOC-PET/CT  should  be the  method  of  choice,  if  available.
© 2014  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Introduction
With an incidence of 0.29/100.000 the malignant forms of neu-
oendocrine neoplasms of the small intestine are a rather rare
ntity.1–4 Though they represent about 30-50% of all small intestine
eoplasms and hence are of high clinical importance.1 Current lit-
rature does not present precise data on recurrence rate in low
rade neuroendocrine tumors (NET).3–7 The tumor proliferation
ate, measured with help of Ki-67 has not only been established for
rading neuroendocrine tumors, but it is also of prognostic value for
ossible tumor recurrence. Following the ENETS guidelines close
ollow-up is necessary even after complete tumor resection and
ven in slow proliferating tumors. In this case report we present a
4 year old female with recurrence of a slow proliferating neuroen-
ocrine tumor (Ki-67 < 1%) in two locations of the small intestine
t the same time.
. Presentation of caseA 64 year old female with several carcinomas in her family
istory (among others colorectal and gastric) underwent annually
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screening tests including measurement of CA-19.9. In January 2009
an asymptomatic elevation of CA-19.9 (80.3 ku/l) lead to an abdom-
inal CT scan revealing a lesion with hypertrophic and hypervascular
wall of the small intestinal. Reanalysis with CT scan after 3 months
veriﬁed a hypodense, intraluminal lesion, 14 mm in diameter. Diag-
nostic laparoscopy with segmental gut resection was performed
and an intraoperative pathologic examination requested. Histolog-
ical ﬁndings classiﬁed the resected tumor as a high differentiated
neuroendocrine carcinoma with local lymph node involvement
(pT4, N1 (4/9), L1, V0, G1, R0). In consequence Chromogranin A
levels have been measured postoperatively, not showing patho-
logic values (43 g/l). Further staging analysis using somatostatin
receptor scintigraphy (SRS) did not indicate any metastasis.
Due to the slow proliferation rate (Ki-67 < 1%) semiannual
follow-up examinations including CT scan and measurements of
Chromogranin A levels were carried out like proposed in the current
ENETS guidelines.3,4 CT scan in December 2012 revealed hyper-
trophy of the intestinal wall again, this time in two locations
simultaneously. With the patient asymptomatic and tumor mark-
ers at normal levels, active surveillance was  performed for further
6 months and ﬁnally Ga-DOTATOC-PET/CT was done, verifying two
intraluminal lesions of the small intestine measuring 15 mm in
diameter (Figs. 1 and 2). Therefore diagnostic laparoscopy with
resection of the two affected gut segments via mini-laparotomy
was performed. The tumors were localized in the proximal ileum,
about 100 cm oral from the ileocecal region, with a distance of
s Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 1. DOTATOC-PET/CT 06/2013 showing ﬁrst location of tumor recurrence.
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aig. 2. DOTATOC-PET/CT 06/2013 showing second location of tumor recurrence.
5 cm between each other. This time histological exams classiﬁed
he tumors as high differentiated neuroendocrine carcinomas, the
roximal one even with regional lymph node involvement (pT2,
N1 (1/1), G1 and pT1, pN0, G1) (Fig. 3). Proliferation rate was slow
gain with Ki-67 less than 1%.
. DiscussionTumor grading in this case described a high differentiated and
low proliferating NET with Ki-67 < 1%. Despite low proliferation
nd high differentiation we found a bilocal tumor recurrence. With
 distance of 25 cm between the two lesions we can assume an
Fig. 3. Macroscopic appearance of neuroendocrine tumor recurrence.Fig. 4. Typical histological appearance of neuroendocrine carcinoma, 12× zoom:
(A)  tumor, (B) mucosa, (C) muscularis propria, (D) serosa.
independent process of growth. A case of bilocal recurrence has not
yet been described explicitly and is rather uncommon. Regarding
recurrence of NET after surgical R0 resection only two publications
are considered in current guidelines. Moertel described that only
23% of the patients that underwent curative surgery were free of
disease after 25 years.5 Second one is Pape et al. who present 52
cases of tumor recurrence after surgical R0 resection in 139 patients
(37.4%).6 Due to such a lack of long-term results further studies on
recurrence rate and typical localization should be made (Fig. 4).
Diagnostic procedures and operative treatment in this case were
performed according to ENET guidelines with follow-up imaging
every 6–12 months. Between the two tumor manifestations in
2009 and 2013 technical development led to a change in diag-
nostic procedures. Following ENETS guidelines in 2007 SRS has
been proposed for imaging of neuroendocrine tumors. Latest guide-
lines from 2012 prefer Ga-DOTATOC-PET/CT, if available, because
of its higher sensitivity.3,4,8–11 Therefore SRS has been used in 2009
whereas PET-CT revealed tumor recurrence in 2013. Both times
tumor manifestation has been recognized in early state. As PET-CT
provides higher sensitivity, detection of two additional but preexis-
ting lesions which had been missed by SRS in 2009 is theoretically
possible but rather unlikely. For instance assume a bilocal recur-
rence after curative surgical treatment.
4. Conclusion
According recurrence rate of neuroendocrine tumors only few
data is presented in current literature and hence considered in com-
mon  guidelines. Coming research should focus on recurrence rate
and long-time outcomes, especially after R0 resection, of neuroen-
docrine tumors so that follow-up procedures could be adapted.
Following the ENETS guidelines livelong follow-up is essential and
Ga-DOTATOC-PET/CT should nowadays be the diagnostic item of
choice, if available. Even in this case of bilocal tumor recurrence
early tumor detection was possible.
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